| B3 | Preservation of lymphocyte functional fitness in perinatally-infected HIV+ pediatric patients with sub-optimal viral control | E-poster | Determinants of HIV progression and disease control |
| B30 | Rising substance use linked to STI and HCV in Thai MSM after acute HIV infection | On-demand oral abstract session | Substance abuse (including opioid use disorder) |
| B30 | Opioid agonist treatment improves progression through each stage of the HIV cascade of care among people living with HIV who use opioids | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Depression, anxiety, and polysubstance use among persons with HIV: baseline findings from the Promoting Access to Care Engagement (PACE) trial | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Results from a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Anxiety and alcohol consumption in the Miami Adult Studies on HIV (MASH) cohort during the COVID-19 pandemic | E-poster | Substance abuse (including opioid use disorder) |
| B31 | OPTIPRIM 2-ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infection | E-poster | ART in acute infection |
| B32 | Integrase strand transfer inhibitor (INSTI) use and cancer incidence | E-poster | ART in first- and second-line therapies |
| B32 | Antiretroviral therapy for HIV controllers: indications and outcomes in the French ANRS-CO21 CODEX cohort | E-poster | ART in first- and second-line therapies |
| B32 | Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine? | E-poster | ART in first- and second-line therapies |